Beta Bionics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
Rhea-AI Summary
Beta Bionics (Nasdaq: BBNX) will release fourth quarter and full year 2025 financial results after market close on Tuesday, February 17, 2026. Management will host a conference call and concurrent webcast the same day at 4:30 PM ET (1:30 PM PT) to review company performance. The webcast link will be available and later archived in the Investors & Events section at the company website. Phone access for the live call requires registration to obtain dial-in details and a personal PIN.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, VAYK declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
BBNX fell 1.62% while peers were mixed: AHCO -0.66%, SSII -0.72%, IART +1.54%, ESTA +2.22%, INMD +0.36%, suggesting stock-specific trading rather than a unified sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 08 | Prelim Q4 results | Positive | +1.6% | Preliminary Q4 2025 topline results showing strong net sales growth. |
| Dec 08 | Preannounce topline | Neutral | -3.6% | Plan to pre-release Q4 2025 topline metrics and hold investor meetings. |
| Nov 03 | Investor conferences | Neutral | +0.4% | Participation in two healthcare investor conferences with webcast presentations. |
| Oct 28 | Q3 earnings beat | Positive | +2.2% | Q3 2025 results with strong growth and raised full‑year revenue guidance. |
| Oct 09 | Earnings date set | Neutral | +0.5% | Announcement of Q3 2025 earnings release date and conference call details. |
Recent news has mostly been operational and earnings-related, with share price generally rising on positive financial updates and only one notable negative reaction to a neutral pre-announcement.
Over the last few months, Beta Bionics has focused on scaling the iLet Bionic Pancreas and providing frequent financial updates. Q3 2025 results showed strong growth, with net sales of $27.3M and raised full‑year 2025 revenue guidance to above $96.5M. Subsequent earnings date and conference announcements around Oct–Nov 2025 saw modest positive reactions. Preliminary Q4 2025 topline data on Jan 8, 2026 highlighted at least $32.0M in net sales and continued user growth, setting expectations ahead of the scheduled full results on Feb 17, 2026.
Market Pulse Summary
This announcement sets expectations for full Q4 and 2025 results on Feb 17, 2026, following preliminary topline data that already indicated at least $32.0M in Q4 net sales. Historically, Beta Bionics’ stock has reacted modestly positively to detailed earnings releases and guidance updates. Investors may focus on how final figures compare with prior guidance, progress in installed user base, and any updates to commercialization or regulatory timelines disclosed with the upcoming report.
AI-generated analysis. Not financial advice.
IRVINE, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2025 financial results after the financial markets close on Tuesday, February 17, 2026. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company’s fourth quarter and full year 2025 performance.
The link to the webcast will be available on the Company’s website in the “Investors—Events & Presentations” section at https://investors.betabionics.com, and will be archived there for future replay. To access the live call by phone, please use the following link, which will provide you with dial-in details and a personal pin: https://register-conf.media-server.com/register/BI9e198d2306384b3c88c83ffa25a93bcc.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.
Investor Relations:
Blake Beber
Head of Investor Relations
ir@betabionics.com
Media and Public Relations:
Karen Hynes
Vice President of Marketing
media@betabionics.com
Source: Beta Bionics, Inc.
FAQ
When will Beta Bionics (BBNX) report Q4 and full year 2025 results?
What time is the Beta Bionics (BBNX) earnings call and webcast on February 17, 2026?
Where can investors access the Beta Bionics (BBNX) webcast and replay?
How do I join the Beta Bionics (BBNX) live call by phone?
Will the Beta Bionics (BBNX) webcast be available after the live event?
